Recommended

Lilly demonstrates alopecia areata promise in major study
Novartis bets $12bn on potential first-in-class RNA therapeutics
Process analytical tool could aid real-time monitoring in vaccine manufacturing
CPHI Pharma Awards 2025 winners announced
Drug delivery study offers potential “paradigm shift” in restenosis
Lilly AI supercomputer set to advance pharma manufacturing
FDA draft guidance to streamline biosimilar development
Novo Nordisk bids $6.5 billion for Metsera
news

FDA grants Orphan Drug Designation to phenylketonuria treatment

31
SHARES

A new treatment called APR-OD031 has been given Orphan Drug Designation (ODD) by the FDA, for the treatment of phenylketonuria.

Atoms arranged as amino acids

The US Food and Drug Administration (FDA) has announced that it has granted Orphan Drug Designation (ODD) to APR-OD031, for the treatment of phenylketonuria (PKU). The ODD was received by Applied Pharma Research (APR).

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

APR-OD031 is an orally-delivered, extended-release amino acid mix engineered with a patented drug delivery technology enabling the secure physiological absorption of the delivered amino acids in the gut. According to APR, this is the first mix of amino acids having a pharmacological primary mode of action designed to reduce and control phenylalanine fluctuations and muscle proteolysis by reducing catabolic episodes in PKU patients, especially patients who do not respond to Sapropterin.

“The ODD for our drug candidate APR-OD031 is a huge achievement for a small company like APR, which is focusing its efforts on the improvement of PKU standard of care. Together with the other ODD granted six months ago, APR is strengthening its position as a patient-centric company dedicated to major unmet needs in the rare disease space,” said Paolo Galfetti, Chief Executive Officer of APR. “We will work closely with the FDA to complete the development and bring to patients this new drug as soon as possible for the benefit of the PKU community still in the need of innovative and meaningful medications.”

Share via
Share via